Study compares standard against newer treatment in women whose breast cancer has spread

December 07, 2012

(Lebanon, NH, 12/7/12) -- Results from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate with capecitabine, a standard drug used for chemotherapy today in women with previously treated metastatic breast cancer, showed that eribulin demonstrated a trend toward improved overall survival. This study was presented today by Peter A. Kaufman, M.D., during the 2012 CTRC-AACR San Antonio Breast Cancer Symposium.

"We didn't show a statistically significant superiority of eribulin over capecitabine, which was our goal," said Peter A. Kaufman, MD, associate professor of medicine at the Geisel School of Medicine at Dartmouth, and oncologist at Dartmouth-Hitchcock and Norris Cotton Cancer Center in Lebanon, N.H. "However, eribulin demonstrated a trend favoring an overall survival benefit, in comparison to capecitabine, which is a widely accepted and used standard therapy in this setting. Additionally, this is the first study demonstrating that eribulin is active earlier in the course of metastatic breast cancer," Kaufman said.

In 2010, the FDA approved eribulin for the treatment of patients with metastatic breast cancer who had previously received an anthracycline and a taxane and at least two cytotoxic chemotherapy treatment regimens for metastatic breast cancer. The FDA granted approval based on data showing a statistically significant improvement in overall survival compared with current treatments.

Kaufman and colleagues examined whether eribulin would be effective as an earlier-line treatment in women with metastatic breast cancer. They randomly assigned 1,102 patients to eribulin or capecitabine. Patients had all received prior anthracycline- and taxane-based therapy and received the study drug as the first, second or third line of therapy for metastatic disease.

The median overall survival for patients treated with eribulin was 15.9 months compared with 14.5 months for patients treated with capecitabine.

"Although we did not meet our primary endpoints, this is still the first study demonstrating the activity of eribulin in earlier lines of treatment of metastatic breast cancer," Kaufman said. "Eribulin is an active therapy in this setting, and overall, it has potentially comparable activity to capecitabine, which is a widely used treatment in this patient population."

As a next step researchers are evaluating how eribulin performed among subsets of women in the study who share similar traits. Exploratory analyses of patient subsets showed that the median overall survival in women with HER2-negative breast cancer was 15.9 months with eribulin compared with 13.5 months with capecitabine. In women with triple-negative breast cancer, which is a particularly aggressive subset, the median overall survival was 14.4 months with eribulin compared with 9.4 months with capecitabine.

Kaufman and colleagues are still compiling data from the quality-of-life analysis, which according to Kaufman, will help guide their next steps in further studying eribulin in this patient population.
-end-
About Norris Cotton Cancer Center at Dartmouth-Hitchcock:

Norris Cotton Cancer Center combines advanced cancer research at Dartmouth College and the Geisel School of Medicine at Dartmouth with patient-centered cancer care provided at Dartmouth-Hitchcock Medical Center, at Dartmouth-Hitchcock regional locations in Manchester, Nashua, and Keene, NH, and St. Johnsbury, VT, and at 12 partner hospitals throughout New Hampshire and Vermont. It is one of 41 centers nationwide to earn the National Cancer Institute's "Comprehensive Cancer Center" designation. Learn more about Norris Cotton Cancer Center research, programs, and clinical trials online at cancer.dartmouth.edu.

Dartmouth-Hitchcock Medical Center

Related Metastatic Breast Cancer Articles from Brightsurf:

New research supports clinical utility of CTC count for metastatic breast cancer
Menarini Silicon Biosystems, the pioneer of liquid biopsy technology, today announced the publication of a research study providing support for the reliability of using circulating tumor cell (CTC) count to guide frontline therapy choice for patients with estrogen receptor-positive (ER+), HER2-negative (HER2) metastatic breast cancer.

Surgery and radiation do not extend survival in newly diagnosed metastatic breast cancer
Women who present with a new diagnosis of breast cancer that is already in an advanced stage (stage IV) face questions about having surgery and radiation to the tumor in the breast (local therapy).

Novel biomarkers predict benefit with immunotherapy in metastatic breast cancer
Two novel biomarkers have been found to correlate with improved outcomes with immunotherapy in metastatic breast cancer and may help to identify the patients most likely to benefit from this treatment, according to exploratory studies reported at the ESMO Breast Cancer Virtual Meeting 2020.

Activation of a distinct genetic pathway can slow the progress of metastatic breast cancer
Activation of the BMP4 signalling pathway presents a new therapeutic strategy to combat metastatic breast cancer, a disease that has shown no reduction in patient mortality over the past 20 years.

Hyperactive FOXA1 reprograms endocrine-resistant breast cancer to become metastatic
A team led by researchers at Baylor College of Medicine and Harvard Medical School has unveiled a novel mechanism that helps explain how endocrine-resistant breast cancer acquires metastatic behavior, opening the possibility of new therapeutic strategies.

Attacking metastatic breast cancer with sound
Drugs can be safely delivered to cancerous lymph nodes via the lymphatic system and then released inside the nodes using sound waves.

Oncolytics Biotech® and PrECOG announce study in metastatic breast cancer
Oncolytics Biotech® Inc., developing pelareorep, an intravenously delivered immuno-oncolytic virus, and PrECOG LLC, today announced the BRACELET-1 (PrE0113) study, to evaluate the ability of pelareorep to make tumors immunologically visible to checkpoint inhibitors.

Study supports germline testing for all metastatic breast cancer patients
Genetic testing for all metastatic breast cancer patients may be an optimal strategy for identifying additional patients with increased risk as well as response to targeted therapies, according to research published in JAMA Oncology.

Adding targeted therapy to treatment extends lives of those with metastatic breast cancer
A UCLA-led study has found that using a drug called ribociclib in combination with a common hormone therapy may help premenopausal women with the most common type of breast cancer live longer than if they only receive the hormone therapy.

New 'smart drug' shows promise for metastatic triple-negative breast cancer
A clinical trial at NewYork-Presbyterian/Columbia and other centers found that patients responded to a new 'smart drug' for women with an aggressive form of breast cancer.

Read More: Metastatic Breast Cancer News and Metastatic Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.